A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL-GROUP, PHASE 2B STUDY IN TREATMENT-SEEKING PATIENTS WITH CANNABIS USE DISORDER TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AEF0117 IN REDUCING CANNABIS USE

Date Added
June 16th, 2022
PRO Number
Pro00119686
Researcher
Kevin Gray

List of Studies


Keywords
Drug Studies, Substance Use
Summary

The purpose of this research is to investigate how a trial drug, AEF0117, influences the effects of cannabis and if it is helpful in the treatment of Cannabis Use Disorder (CUD). This is a 20-week, randomized, double-blind, placebo-controlled, parallel-group outpatient clinical trial that will be conducted at approximately 10 research sites in the US.

Institution
MUSC
Recruitment Contact
Amanda Wagner
843-792-0484
wagne@musc.edu

Cytochrome P450 and Subjective Cannabis Response in Youth Cannabis Use Disorder

Date Added
March 2nd, 2021
PRO Number
Pro00107842
Researcher
Kevin Gray

List of Studies


Keywords
Adolescents, Genetics, Psychiatry, Substance Use
Summary

Eligible adolescents and emerging adults (ages 12-25) who have used cannabis in the past year will attend 1-2 laboratory visits. They will complete a series of interviews and self-report measures, including assessment of cannabis quantity and frequency, subjective effects of cannabis, and problems due to cannabis use. They will provide a urine sample for analysis of a THC metabolite and they will provide a blood sample for analysis of genes related to cytochrome P450 enzyme activity, which are thought to be associated with metabolism of THC.

Institution
MUSC
Recruitment Contact
Youth Collaborative
843-792-9257
youth@musc.edu

A Proof-of-Concept Trial of N-Acetylcysteine for Adolescent Alcohol Use Disorder

Date Added
September 4th, 2018
PRO Number
Pro00080921
Researcher
Kevin Gray

List of Studies


Keywords
Adolescents, Alcohol, Substance Use
Summary

The purpose of this study is to evaluate the efficacy of the medication N-acetylcysteine (NAC) to help young people with alcohol use disorder. NAC is an over-the-counter supplement and antioxidant that has been approved by the Food and Drug Administration (FDA) in adults and children for other uses, but has not been approved by the FDA for treatment of alcohol use disorder. All participants will receive brief alcohol counseling during the 8 weeks of medication treatment. Volunteers ages 13-25 are needed for this study.

Institution
MUSC
Recruitment Contact
Youth Collaborative Intake
843-792-9257
youth@musc.edu

N-Acetylcysteine for Youth Cannabis Use Disorder

Date Added
May 3rd, 2016
PRO Number
Pro00054499
Researcher
Kevin Gray

List of Studies


Keywords
Adolescents, Substance Use
Summary

The purpose of this study is to evaluate the efficacy of the medication N-acetylcysteine (NAC) to help young people quit using marijuana. NAC is an over-the-counter supplement and antioxidant that has been approved by the Food and Drug Administration (FDA) in adults and children for other uses, but has not been approved by the FDA for treatment of marijuana use disorder. Volunteers ages 13-21 are needed for this study.

Institution
MUSC
Recruitment Contact
Intake Team
843-792-9257
youth@musc.edu



-- OR --